Arthur He Reiterates Buy on Jade with Unchanged $45 Price Target Ahead of Key JADE101 Phase 1 Data

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Jade Biosciences, with a price target of $45.00.

Arthur He CFA has given his Buy rating due to a combination of factors, including the upcoming Phase 1 data for JADE101 at the ERA Congress and the drug’s differentiated profile versus first-generation APRIL inhibitors. He views the biomarker-rich readout as a key stock catalyst, with a base-case scenario of robust IgA reductions and a convenient quarterly dosing schedule that could support best-in-class positioning in IgA nephropathy.

He also highlights steady advancement of Jade’s broader pipeline, including JADE201 and JADE301, which expands the company’s reach across B‑cell–mediated autoimmune diseases and supports longer-term value creation. In addition, he notes that Jade’s roughly $311M cash balance should fund operations into 1H28, providing adequate runway through multiple clinical milestones, and therefore maintains a Buy rating with an unchanged $45 price target.

In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $34.00 price target.